Brokerage firm Morgan Stanley Downgrades its rating on Infinity Pharmaceuticals(NASDAQ:INFI). In a research note issued to the investors, the brokerage major Lowers the price-target to $1.00 per share. The shares have been rated Equal-weight. Previously, the analysts had a Overweight rating on the shares. The rating by Morgan Stanley was issued on Jun 15, 2016.
In a different note, On Jun 14, 2016, JMP Securities said it Downgrades its rating on Infinity Pharmaceuticals. The shares have been rated ‘Market Perform’ by the firm. On Jun 14, 2016, Wedbush said it Upgrades its rating on Infinity Pharmaceuticals. In the research note, the firm Lowers the price-target to $3.00 per share. The shares have been rated ‘Neutral’ by the firm. On Mar 22, 2016, Wedbush said it Downgrades its rating on Infinity Pharmaceuticals. In the research note, the firm Lowers the price-target to $8.00 per share. The shares have been rated ‘Underperform’ by the firm.
Infinity Pharmaceuticals (INFI) shares turned negative on Tuesdays trading session with the shares closing down -0.07 points or -5.04% at a volume of 21,34,884. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.439. The peak price level was also seen at $1.439 while the days lowest was $1.3. Finally the shares closed at $1.32. The 52-week high of the shares is $11.75 while the 52-week low is $1.24. According to the latest information available, the market cap of the company is $65 M.
Infinity Pharmaceuticals(INFI) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $9.26M. Analysts had an estimated revenue of $8.80M. Earnings per share were $-0.82. Analysts had estimated an EPS of $-0.82.
Several Insider Transactions has been reported to the SEC. On Jun 26, 2015, Adelene Q Perkins (President & CEO) sold 5,000 shares at $10.93 per share price.Also, On Jun 16, 2015, Vito J. Palombella (Chief Scientific Officer) sold 4,737 shares at $10.97 per share price.
Infinity Pharmaceuticals Inc. is a biopharmaceutical company that is engaged in the discovery development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib also known as IPI-145 an oral dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. In addition to duvelisib the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies) a worldwide investigation of duvelisib in blood cancers.